title: Hepatitis C virus infection in patients with B-cell non-Hodgkin's lymphoma.
abstract: OBJECTIVE
  As a causative role of hepatitis C virus (HCV) in B-cell lymphoproliferative disorders (LPD) has been suggested by several reports, we investigated the prevalence of HCV infection among patients with LPD at our hospital with the aim of clarifying the clinical features and the outcome for HCV antibody-positive patients with non-Hodgkin's lymphoma (NHL).
  
  
  METHODS
  Retrospective chart review.
  
  
  METHODS
  A total of 123 patients with B-cell LPD (4 with chronic lymphocytic leukemia, 17 with multiple myeloma, and 100 with B-cell NHL), 38 patients with non-B-cell LPD (5 with adult T-cell lymphoma, 8 with Hodgkin's disease, and 25 with non-B-cell NHL) and 516 patients with miscellaneous diseases other than liver diseases or LPD (control) were studied.
  
  
  RESULTS
  HCV infection was detected in 17 of 100 patients with B-cell NHL versus none of 25 patients with non-B-cell NHL (p=0.023) and in 34 patients (6.6%) in the control group with miscellaneous diseases (p=0.0011). In HCV-positive B-cell NHL, primary liver involvement was detected in 3 of 17 patients compared to none of 83 HCV-negative patients (p=0.0019). Intermediate-grade lymphoma (Working Formulation) was the most frequent histology. Eleven of 15 HCV-positive patients achieved complete remission after chemotherapy, and 6 of 7 deaths were caused by liver-related diseases.
  
  
  CONCLUSIONS
  The prevalence of HCV infection was higher in patients with B-cell NHL than in those with non-B-cell NHL and the control group. Primary liver involvement and liver-related causes of death were frequent in HCV-positive patients with B-cell NHL.
authors.affiliation: Department of Internal Medicine I, Daisan Hospital, Jikei University School of Medicine, Komae, Tokyo.
authors.forename: F
authors.initials: F
authors.lastname: Mizorogi
authors.forename: J
authors.initials: J
authors.lastname: Hiramoto
authors.forename: A
authors.initials: A
authors.lastname: Nozato
authors.forename: Y
authors.initials: Y
authors.lastname: Takekuma
authors.forename: K
authors.initials: K
authors.lastname: Nagayama
authors.forename: T
authors.initials: T
authors.lastname: Tanaka
authors.forename: K
authors.initials: K
authors.lastname: Takagi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D016174:Hepacivirus / Q000235:genetics / Q000276:immunology; D006526:Hepatitis C / Q000150:complications* / Q000175:diagnosis / Q000453:epidemiology; D018937:Hepatitis C Antibodies / Q000032:analysis; D006801:Humans; D007564:Japan / Q000453:epidemiology; D016393:Lymphoma, B-Cell / Q000175:diagnosis / Q000453:epidemiology / Q000821:virology*; D008297:Male; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D015995:Prevalence; D011379:Prognosis; D012367:RNA, Viral / Q000032:analysis; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D018937:Hepatitis C Antibodies; D012367:RNA, Viral